|
Indian Journal of Medical Microbiology, Vol. 29, No. 3, July-September, 2011, pp. 317-318 Correspondence Penicillin resistant Streptococcus pneumoniae in India: Effects of new clinical laboratory standards institute breakpoint and implications B Veeraraghavan1, T Kurien2 1 Department of Clinical Microbiology, PI- South East Asian Pneumococcal Network Alliances, Christian Medical College and Hospital, Vellore - 632 004, Tamil Nadu, India Date of Submission: 13-Feb-2009 Code Number: mb11079 PMID: 21860122 DOI: 10.4103/0255-0857.83925 Dear Editor, India has the lowest incidence of penicillin-resistant Streptococcus pneumoniae (PRSP) among the Asian countries. [1] A gradual increase in the intermediate resistance to penicillin (IRP) has been documented in India since 1995. [2],[3],[4],[5],[6],[7] The minimum inhibitory concentration (MIC) penicillin breakpoints for S. pneumoniae [Table - 1] that are recommended by Clinical Laboratory Standards Institute (CLSI) were used for interpretation and quality control in present studies. In 2008, new penicillin breakpoints for S. pneumoniae [Table - 1] were published by CLSI. [8] Consequently, we revisited and applied new CLSI breakpoints to ours as well as to other published Indian studies on IRP/PRSP data. The published studies on S. pneumoniae IRP included, 3.8% in 1996-1997; [1] 1.48% in 1993 -1997 and 7.8% in 2000-2001 [1] among clinical isolates. [2] On re-evaluation, with the new CLSI breakpoints, considering, nonmeningitis, invasive isolates requiring intravenous penicillin therapy. These percentages changed to ≤1%. Likewise, the studies reported by other groups in India may also be overlooked because, as per the new breakpoints, most S. pneumoniae IRP isolates fall into susceptible range, i.e., 7.3% (n=11) (with exception of three CSF isolates) with penicillin MIC between 0.1 and 1 μg/mL; [4] 15.4% (n = 2) 0.75 and 0.125 μg/mL [5] and 25% (n = 3) with 0.19, 0.25, 0.38 μg/mL; [6] 20% (n=30) with 0.12-1 μg/mL and 2 μg/mL of 26 and 4 respiratory isolates, respectively. [7] Conversely, in 1999, [3] a 4.6% ( n=25) which included eight CSF isolates with intermediate resistant to penicillin (0.125-1.0 μg/mL) was reported and yet another study with three CSF isolates with penicillin MIC between 0.1 and 1 μg/mL[4] changes to complete resistant (≤ 0.06 μg/mL susceptible; ≥0.12 μg/mL resistant and with no intermediate breakpoint recommendation, because blood brain barrier reduces the infiltration of penicillin into cerebrospinal fluid) as per the new CLSI break point. This obviously confirms the pre-existence of PRSP causing invasive disease in India. From this analysis, we conclude that the overall percentage determined as IRP is significantly reduced with the new CLSI breakpoint recommendation for non-meningitis isolates. Therefore penicillin is a preferred drug to treat non-meningitis S. pneumoniae infection. Further, microbiologists should encourage the prescription of narrow spectrum penicillin rather than broader spectrum antimicrobials, especially cephalosporins and fluoroquinolones. This may prevent the globally emergent multidrug resistant S. pneumoniae (especially serotype 19A, which are currently susceptible to penicillin; unpublished data) and greatly reduce the development and spread of hospital- and community-acquired infections due to antimicrobial resistance. The additional emphasis includes
References
Copyright 2011 - Indian Journal of Medical Microbiology The following images related to this document are available:Photo images[mb11079t1.jpg] |
|